

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/699,517		
		Filing Date	October 31, 2003		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1649		
		Examiner Name	Kolker, Daniel E.		
Sheet	1	of	2	Attorney Docket Number	015270-008920US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	249	US-7,479,482 B2	01-20-0209	Frangione et al.	
	251	US-7,014,855 B2	03-21-2006	Schenk	
	252	US-6,972,127 B2	12-06-2005	Schenk	
	253	US-6,946,135 B2	09-20-2005	Schenk et al.	
	254	US-2005/0123544 A1	06-09-2005	Schenk et al.	
	250	US-6,787,523 B1	09-07-2004	Schenk	
	248	US-2004/0197831 A1	10-07-2004	Weksler et al.	
	256	US-2003/0165496 A1	09-04-2003	Basi et al.	
	239	US 5,807,741	09-15-1998	Brown et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **2**of **2****Complete If Known**

Application Number	10/699,517
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	240	ALVES DA COSTA, "Recent Advances on α -Synuclein Cell Biology : Functions and Dysfunctions," Current Molecular Medicines, 3:17-24 (2003).	<input type="checkbox"/>
	241	CASADESUS et al., "The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease," Drugs R&D, 7(3):187-193 (2006).	<input type="checkbox"/>
	242	JANEWAY et al., <i>Immunology</i> , 3 rd edition, 8:18-8:19 (1997).	<input type="checkbox"/>
	255	PCT Search report of 04/07/2009 for application PCT/US08/02392	<input type="checkbox"/>
	243	PERRIN et al., "Epitope mapping and specificity of the anti- α -synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines," <i>Neuroscience Letters</i> , 349:1331-1335 (2003), abstract only.	<input type="checkbox"/>
	244	SIDHU et al., "Does α -synuclein modulate dopaminergic synaptic content and tone at the synapse," FASEB, 18:637-647 (2004).	<input type="checkbox"/>
	245	SPILLANTINI et al., " α -Synuclein in Lewy bodies," <i>Nature</i> , 388:839-840 (1997).	<input type="checkbox"/>
	246	TAKEDA et al., "Abnormal Accumulation of NACP/ α -Synuclein in Neurodegenerative Disorders," <i>American Journal of Pathology</i> , 152:367-372 (1998).	<input type="checkbox"/>
	247	TOFARIS et al., "Physiological and Pathological Properties of α -synuclein," <i>Cellular and Molecular Life Sciences</i> , pp. 1-8 (2007).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.